Global Veterinary Molecular Diagnostics Market Size study, by Product, Animal Type, Technology, Application, End-use and Regional Forecasts 2022-2032

Global Veterinary Molecular Diagnostics Market is valued approximately at USD 1.12 billion in 2023 and is anticipated to grow with an impressive CAGR of more than 10.50% over the forecast period 2024–2032. The burgeoning field of veterinary molecular diagnostics is fundamentally reshaping how animal diseases are identified, monitored, and managed. With the surge in zoonotic diseases, heightened sensitivity to animal welfare, and the critical need for precision-driven veterinary care, molecular diagnostic tools have emerged as indispensable assets across both companion and livestock animal sectors. By leveraging technologies such as PCR, microarrays, and next-generation sequencing, these tools offer rapid, reliable, and highly specific insights into pathogen presence, genetic disorders, and antimicrobial resistance—all at the molecular level.

This surge in demand can largely be attributed to the increasing adoption of point-of-care diagnostics, a rise in pet ownership worldwide, and the exponential growth in livestock farming to meet global protein demands. Simultaneously, the veterinary healthcare community is gravitating toward preventive medicine, where early detection of diseases ensures timely intervention, thereby minimizing economic losses and curbing outbreaks. Advances in diagnostic accuracy, coupled with expanding availability of multiplex testing and portable molecular platforms, are further catalyzing this transition. These solutions are not only streamlining workflows in veterinary clinics and research labs but also empowering field veterinarians in remote or resource-constrained settings.

Yet, the path to widespread adoption is not without obstacles. The high costs associated with equipment and reagents, particularly in low-to-middle income regions, pose financial constraints. Additionally, a lack of skilled professionals and limited awareness regarding advanced molecular testing in rural veterinary settings slow down penetration. However, global initiatives for veterinary health infrastructure development and collaborative training programs are beginning to bridge these gaps. Moreover, continuous investments in R&D and integration with digital technologies such as AI and cloud-based diagnostic management systems are expected to democratize access and improve cost-efficiency in the long term.

As molecular diagnostics evolve, the focus is shifting toward next-gen innovations such as real-time pathogen monitoring, syndromic testing panels, and companion animal genomics. These trends are fueling strategic collaborations between biotech companies, veterinary hospitals, and academic institutions to deliver customized, species-specific diagnostic solutions. Notably, the market is experiencing a rise in demand for molecular diagnostics tailored to detect emerging and re-emerging animal diseases—supporting biosecurity across borders and aiding in the control of transboundary animal diseases that threaten global food security.

Regionally, North America holds a commanding position in the global veterinary molecular diagnostics market, backed by cutting-edge infrastructure, extensive companion animal expenditure, and robust regulatory frameworks. Europe follows closely, driven by proactive government policies surrounding animal health surveillance and precision livestock farming initiatives. Meanwhile, Asia Pacific is projected to grow at the highest CAGR over the forecast period, owing to rising disposable incomes, increasing pet adoption, and growing awareness of infectious disease control in high-density farming nations like China and India. Latin America and the Middle East & Africa are also witnessing a gradual uptake, primarily due to international funding and expanding veterinary education systems.

Major market player included in this report are:
• IDEXX Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• Zoetis Inc.
• Neogen Corporation
• QIAGEN N.V.
• Heska Corporation
• Randox Laboratories Ltd.
• Agilent Technologies Inc.
• Bioneer Corporation
• Creative Diagnostics
• Biocheck B.V.
• Eurofins Scientific
• Biogal Galed Labs
• VMRD, Inc.

The detailed segments and sub-segment of the market are explained below:

By Product
• Instruments
• Reagents & Kits
• Software & Services

By Animal Type
• Companion Animals

o Dogs

o Cats

o Others
• Livestock Animals

o Cattle

o Poultry

o Swine

o Others

By Technology
• PCR (Polymerase Chain Reaction)
• Microarrays
• DNA Sequencing
• Other Technologies

By Application
• Pathogen Detection
• Genetic Testing
• Pharmacogenomics
• Others

By End-use
• Veterinary Hospitals & Clinics
• Reference Laboratories
• Research Institutes & Universities
• Others

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.